ANALYSIS: With an Obermatt 360° View of 50 (better than 50% compared with alternatives), overall professional sentiment and financial characteristics for the stock Hikma Pharmaceuticals are above average. The 360° View is based on consolidating four consolidated indicators, with half the metrics below and half above average for Hikma Pharmaceuticals. The consolidated Value Rank has an attractive rank of 89, which means that the share price of Hikma Pharmaceuticals is on the lower side compared with the typical size in indicators such as revenues, profits, and invested capital. This means that the stock price is lower than for 89% of alternative stocks in the same industry. The consolidated Sentiment Rank has a good rank of 75, which means that professional investors are more optimistic about the stock than for 75% of alternative investment opportunities. But the consolidated Growth Rank has a low rank of 25, which means that the company exhibits below-average growth momentum when looking at financial metrics such as revenue, profit, invested capital growth, and stock returns. The consolidated Safety Rank has a riskier rank of 27, meaning the company has a riskier financing structure than 73 comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. ...read more